Global Heparin Market 2015-2019 - Key Vendors are Aspen, Leo Pharma, Pfizer & Sanofi-Aventis

Heparin is an anticoagulant or blood thinner produced by basophils and mast cells. Though it has no effect on already formed clots, it enables the body's natural clot lysis mechanisms to function and dissolve clots. A porcine intestine or bovine lungs extract of heparin is used pharmaceutically in conditions such as DVT, pulmonary embolism, acute coronary syndrome, and atrial fibrillation to prevent clots. It is also used during surgeries to prevent clot formation.

The anti-inflammatory activity of heparin is a recent discovery. Heparin exhibits this trait through the neutralization of cationic mediators, inhibition of adhesion molecules, and the inhibition of heparanase, all of which are involved in leukocyte recruitment into tissues. Further studies are being conducted to exploit the use of heparin as an anti-inflammatory agent.

According to the report, the growing prevalence of diseases is one of the key drivers of the market. Diseases such as coronary heart disease, kidney disorders, stroke, and inflammatory conditions are a result of blood clots, leading to a rise in the demand for heparin drugs.

Further, the report states that the patent expiry of top-selling drugs is a major challenge to vendors in the market, leading to the entry of generic drugs in the market and, consequently, a reduction in the price of branded drugs.

To calculate the market size, the report considers revenue generated from the sales of generic and branded therapeutic products, including

Key Vendors

Other Prominent Vendors

Key Topics Covered:

For more information visit http://www.researchandmarkets.com/research/f9k5fz/global_heparin

Media Contact: Laura Wood , +353-1-481-1716, [email protected]